VRTX241213C490000
- 6.00
- -2.62-30.39%
Vertex Pharmaceuticals Newsroom
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Market Falls Wednesday, but Googles Chip Impresses | WST
10 Health Care Stocks With Whale Alerts In Today's Session
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Jefferies follows JPMorgan's call on Vertex Pharmaceuticals (VRTX.US) and raises the target price to $550.
Based on fundamentals and product pipeline, jefferies financial has upgraded vertex pharmaceuticals to buy.
Vertex Upgraded to Buy by Jefferies on Fundamentals, Pipeline
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Vertex Reports Positive Long-term Data for Casgevy
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
Vertex Pharmaceuticals Analyst Ratings
Jefferies Upgrades Vertex Pharmaceuticals to Buy From Hold, Adjusts Price Target to $550 From $500
Jefferies Upgrades Vertex Pharmaceuticals(VRTX.US) to Buy Rating, Raises Target Price to $550
Express News | Vertex Pharmaceuticals Inc : Jefferies Raises to Buy From Hold
Express News | Reported Sunday, Vertex Highlights Long-Term Benefits Of CASGEVY For Sickle Cell Disease And Beta Thalassemia At ASH 2024
Vertex Pharmaceuticals Presents Long-term Data on CASGEVY at ASH
Weekly Buzz: Now THOSE are records!!
Index Records are BACK for Friday Market While Unemployment Climbs | Live Stock